• 參考資料PM-COR-22-112808

    1. Elidel® (pimecrolimus) Prescribing Information. Viatris Healthcare Hong Kong: Version September 2022.
    2. Luk D, Hon KLE, Dizon MVC, et al. Practical recommendations for the topical treatment of atopic dermatitis in South and East Asia. Dermatol Ther (Heidelb). 2021;11(1):275-291.
    3. Luger T, De Raeve L, Gelmetti C, et al. Recommendations for pimecrolimus 1% cream in the treatment of mild-to-moderate atopic dermatitis: from medical needs to a new treatment algorithm. Eur J Dermatol. 2013;23(6):758-766.
    4. Jensen JM, Pfeiffer S, Witt M, et al. Different effects of pimecrolimus and betamethasone on the skin barrier in patients with atopic dermatitis. J Allergy Clin Immunol. 2009;123(5):1124-1133.
    5. Aschoff R, Schwanebeck U, Brautigam M, Meurer M. Skin physiological parameters confirm the therapeutic efficacy of pimecrolimus cream 1% in patients with mild-to-moderate atopic dermatitis. Exp Dermatol. 2009;18(1):24-29.
    6. Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: Part I. J Eur Acad Dermatol Venereol. 2018;32(5):657-682.